Drug Trial Radar · NCT07391774
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,978
Planned (sponsor's estimate)
Start
Aug 10, 2026
Primary completion
Jul 31, 2029
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Feb 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy, with letrozole, anastrozole or exemestane, lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormone therapy plus ribociclib may work as well as chemotherapy followed by hormone therapy plus ribociclib for the treatment of high anatomic stage breast cancer with low recurrence risk.
Conditions
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Estrogen Receptor-Positive Breast Carcinoma
- HER2-Negative Breast Carcinoma
Interventions
AnastrozoleDrug
Given PO
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone ScanProcedure
Undergo bone scan
ChemotherapyDrug
Receive standard of care chemotherapy
Computed TomographyProcedure
Undergo CT scan
ExemestaneDrug
Given PO
LetrozoleDrug
Given PO
Oncotype DX Breast Cancer AssayProcedure
Undergo risk recurrence testing
Positron Emission TomographyProcedure
Undergo FDG PET scan
Ribociclib SuccinateDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive breast cancer-free survival (iBCFS)Time frame: From randomization to invasive disease or death, up to 10 years
Locations
264 sites in 2 countries. Site status is shown where the registry gives one.
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas · Recruiting
Sutter Auburn Faith Hospital
Auburn, California · Recruiting
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California · Recruiting
Tower Cancer Research Foundation
Beverly Hills, California · Recruiting
Palo Alto Medical Foundation-Fremont
Fremont, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
Memorial Medical Center
Modesto, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Palo Alto Medical Foundation Health Care
Palo Alto, California · Recruiting
Stanford Cancer Institute Palo Alto
Palo Alto, California · Recruiting
Huntington Memorial Hospital
Pasadena, California · Recruiting
Sutter Roseville Medical Center
Roseville, California · Recruiting
Sutter Medical Center Sacramento
Sacramento, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
California Pacific Medical Center-Pacific Campus
San Francisco, California · Recruiting
Stanford Cancer Center South Bay
San Jose, California · Recruiting
Mills Health Center
San Mateo, California · Recruiting
Ridley-Tree Cancer Center
Santa Barbara, California · Recruiting
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California · Recruiting
Cedars-Sinai Cancer - Tarzana
Tarzana, California · Recruiting
Sutter Solano Medical Center/Cancer Center
Vallejo, California · Recruiting
UCI Health - Yorba Linda
Yorba Linda, California · Recruiting
Saint Anthony North Hospital
Westminster, Colorado · Recruiting
Stamford Hospital/Bennett Cancer Center
Stamford, Connecticut · Recruiting
Beebe South Coastal Health Campus
Millville, Delaware · Recruiting
Helen F Graham Cancer Center
Newark, Delaware · Recruiting
Medical Oncology Hematology Consultants PA
Newark, Delaware · Recruiting
Beebe Health Campus
Rehoboth Beach, Delaware · Recruiting
The Watson Clinic
Lakeland, Florida · Recruiting
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho · Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho · Recruiting
Illinois CancerCare-Bloomington
Bloomington, Illinois · Recruiting
Illinois CancerCare-Canton
Canton, Illinois · Recruiting
SIH Cancer Institute
Carterville, Illinois · Recruiting
Illinois CancerCare-Carthage
Carthage, Illinois · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Northwestern Medicine Cancer Center Old Irving Park
Chicago, Illinois · Recruiting
Carle at The Riverfront
Danville, Illinois · Recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois · Recruiting
Showing 40 of 264 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.